Screener
Bristol-Myers Squibb BMY Other revenue — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
| Dollars in millions | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Abraxane | 55 | 105 | 105 | 210 |
| Other Legacy products(b) | 170 | 223 | 326 | 421 |
| Total Legacy Portfolio | 5,422 | 5,673 | 10,699 | 11,311 |
| Other revenue(c) | (9) | — | (23) | — |
| Total Revenues | $12,973 | $12,269 | $24,462 | $23,470 |
| United States | $8,991 | $8,519 | $16,779 | $16,392 |
| International | 3,664 | 3,481 | 7,108 | 6,590 |
| Other(d) | 318 | 270 | 575 | 488 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's other revenue — total revenues?
- Bristol-Myers Squibb (BMY) reported other revenue — total revenues of -$9M in Q2 2026.
- What does other revenue — total revenues mean?
- This metric represents revenue generated from activities outside of the company's core pharmaceutical product sales, including hedging activities and miscellaneous income streams. It captures non-core financial gains or losses that impact the total top-line performance but are not directly tied to the commercialization of therapeutic drugs. Monitoring this helps investors understand the impact of financial risk management and ancillary business operations on overall revenue stability.
Ask your AI about Bristol-Myers Squibb's other revenue — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude